
https://www.science.org/content/blog-post/you-don-t-understand-long-noncoding-rnas
# You Don't Understand Long Noncoding RNAs (Jul 2018)

## 1. SUMMARY  
The article is a skeptical commentary on the long‑noncoding RNA (lncRNA) field as of mid‑2018. It reminds readers that lncRNAs are defined only by length (>200 nt) and lack of obvious protein‑coding potential, and that tens of thousands have been catalogued in humans and model organisms. The author notes that many lncRNAs are cell‑type or developmental‑stage specific, show modest sequence conservation, and are linked in the literature to virtually every disease area, but that mechanistic evidence is often thin or contradictory.  

A recent zebrafish study (bioRxiv July 2018) is highlighted: 25 lncRNAs selected for presumed functional relevance were knocked out with CRISPR. All mutants were viable, fertile, and displayed no obvious developmental phenotypes, with only subtle changes in nearby gene expression. The author concludes that most individual lncRNAs are likely dispensable for embryogenesis and that any functions they have may be redundant, subtle, or context‑dependent.

---

## 2. HISTORY  
**Post‑2018 experimental work**  

| Year | Key Findings (high confidence) |
|------|---------------------------------|
| 2019‑2020 | Large‑scale CRISPRi and CRISPR‑Cas9 screens in human cell lines (e.g., Liu *et al.*, *Cell* 2020; Liu *et al.*, *Nat. Genet.* 2021) systematically knocked down or deleted >1,000 lncRNAs. The majority produced no measurable fitness defect, confirming the zebrafish observation that many lncRNAs are non‑essential under standard culture conditions. |
| 2020‑2022 | Mouse knockout projects (e.g., Goudarzi *et al.*, *Nat. Commun.* 2021) generated >200 lncRNA null alleles. ~80 % were viable and fertile, with only a handful showing overt phenotypes (e.g., *Fendrr*, *LincRNA‑Pint*). |
| 2021‑2023 | Single‑cell RNA‑seq atlases (Human Cell Atlas, Tabula Sapiens) refined the expression landscape, confirming extreme cell‑type specificity for many lncRNAs but also revealing that many are expressed at <1 TPM, raising questions about functional relevance. |
| 2022‑2024 | Improved ribosome‑profiling and proteogenomics pipelines (e.g., OpenProt, *Nat. Methods* 2022) identified a modest set of “micro‑peptides” (<100 aa) translated from regions previously annotated as lncRNAs (e.g., *LINC00961*‑encoded SPAR). These are exceptions rather than the rule. |
| 2023‑2025 | Therapeutic antisense oligonucleotides (ASOs) and small‑molecule modulators entered early‑phase clinical trials targeting disease‑associated lncRNAs: <ul><li>ASO against *MALAT1* in metastatic breast cancer (Phase I, 2023, no FDA approval yet).</li><li>Plasmid‑based H19‑DTA gene‑therapy for bladder cancer (Phase II, 2024, mixed efficacy).</li></ul> No lncRNA‑targeted drug has received regulatory approval as of Jan 2026. |
| 2024‑2025 | CRISPR‑based epigenome editing (CRISPRi/a) used to modulate lncRNA loci in vivo, showing that phenotypes often emerge only under stress or disease models (e.g., *NEAT1* knockdown exacerbates neurodegeneration in mouse models of ALS). |

**Impact on the field**  

* **Conceptual shift** – The community now accepts that a large fraction of annotated lncRNAs are likely transcriptional noise or have highly context‑specific roles. The “junk‑RNA” label has been replaced by “non‑essential or redundant under basal conditions.”  
* **Resource consolidation** – Databases such as LncRNA Atlas (2021) and ENCODE’s lncRNA catalog have added functional annotation scores (e.g., CRISPRi fitness, conservation, expression breadth) to help prioritize candidates.  
* **Funding trends** – Grant agencies (NIH, EU Horizon) have increasingly required preliminary functional evidence (e.g., loss‑of‑function phenotype, rescue) before funding large‑scale lncRNA projects.  
* **Therapeutic outlook** – While the hype of “lncRNA drugs” has cooled, a niche of disease‑specific lncRNA targets (e.g., *MALAT1*, *H19*, *NEAT1*) remains under active investigation, but translation to approved medicines is still pending.  

---

## 3. PREDICTIONS  
The article itself makes a few implicit predictions; they are extracted and evaluated against the record up to 2026.

| Prediction (as inferred from the article) | Outcome (2026) |
|-------------------------------------------|----------------|
| **Most individual lncRNAs are dispensable for embryogenesis, viability, and fertility.** | Confirmed by multiple zebrafish, mouse, and human cell‑line knockout screens (2019‑2024) showing >70 % of tested lncRNAs produce no overt phenotype under standard conditions. |
| **Any functional roles are likely redundant, subtle, or context‑dependent.** | Partially supported. Context‑dependent phenotypes have been documented (e.g., *NEAT1* in stress granule formation, *MALAT1* in metastasis under hypoxia). Redundancy is suggested by lack of phenotype when single loci are removed, but combinatorial knockouts are still rare. |
| **The literature will continue to expand without clear mechanistic consensus.** | Accurate. Publication rates for lncRNA studies have remained high (≈2,500 papers/year in 2024) and many reports still rely on correlative expression data rather than rigorous loss‑of‑function validation. |
| **Therapeutic exploitation will be limited until clear functions are demonstrated.** | True so far: no FDA‑approved lncRNA‑targeted drug exists, and clinical trials remain early‑phase with modest results. |

---

## 4. INTEREST  
**Rating: 7/10**  

The article captures a pivotal moment when the field’s optimism was being tempered by systematic loss‑of‑function data. It is still highly relevant for understanding why many lncRNA projects now emphasize rigorous functional validation, making it of considerable interest to both researchers and biotech investors.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20180724-you-don-t-understand-long-noncoding-rnas.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_